CRDF · Cardiff Oncology, Inc. · Executive Compensation

$0.91 +0.01 (+1.59%) Q4 2024 earnings call transcript

Market Cap

$69.83M

77.80M

Volume · Oct 29 123.21K Avg daily vol (3M) 679.76K

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mark Erlander	CEO	$635,000	—	—	$2,266,106	$122,238	—	$3,023,344
Roger Sidhu	CMO	$279,370	—	—	$1,920,275	$74,160	—	$2,273,805
James Levine	CFO	$490,000	—	—	$993,875	$61,740	—	$1,545,615

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mark Erlander	CEO	$610,584	—	—	$1,471,762	$319,030	—	$2,401,376
Fairooz Kabbinavar	CMO	$494,400	—	—	$591,614	$186,883	—	$1,272,897
James Levine	CFO	$471,194	—	—	$591,614	$203,556	—	$1,266,364

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mark Erlander	CEO	$594,400	—	—	$672,978	$280,394	—	$1,547,772
Fairooz Kabbinavar	CMO	$443,865	—	—	$601,468	$212,120	—	$1,257,453
James Levine	CFO	$459,236	—	—	$275,678	$182,805	—	$917,719

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Tod Smeal	CSO	$402,716	$40,000	—	$1,487,292	$156,825	—	$2,086,833
Mark Erlander	CEO	$570,600	—	—	$753,272	$266,475	—	$1,590,347
James Levine	CFO	$440,475	—	—	$350,752	$168,252	—	$959,479

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mark Erlander	CEO	$532,716	—	—	$2,851,972	$250,510	—	$3,635,198
James Levine	CFO	$202,693	—	—	$2,085,227	$179,775	—	$2,467,695
Vicki Kelemen	COO	$359,962	—	—	$1,317,635	$152,280	—	$1,829,877

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mark Erlander	CEO	$444,764	—	—	$476,380	$229,559	—	$1,150,703
Vicki Kelemen	COO	$322,576	—	—	$269,543	$157,500	—	$749,619

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Thomas H. Adams	CEO	$491,132	—	—	$568,877	$244,625	—	$1,304,634
Mark Erlander	CSO	$398,729	—	—	$255,622	$198,600	—	$852,951

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mark Erlander	CSO	$387,155	—	$34,785	$144,008	$342,576	—	$908,524
Thomas H. Adams	CEO	$286,346	—	—	$11,679	$79,167	—	$377,192

Executive changes

Person	Role	Change	Effective	Filed
Dr. Leila Alland	interim Chief Medical Officer	Appointed	2026-10-23	2026-10-27
Dr. Roger Sidhu	Chief Medical Officer	Resigned	2026-10-22	2026-10-27
Mani Mohindru, Ph.D.	President and Chief Executive Officer	Appointed	—	2026-04-09
Ajay Aggarwal, MD, MBA	Chief Operating Officer	Appointed	2026-04-27	2026-04-09
Josh Muntner	Chief Financial Officer	Appointed	2026-04-06	2026-04-09
Dr. Mark Erlander	director	Resigned	2026-03-27	2026-04-02
Brigitte Lindsay	Chief Accounting Officer	Appointed	2026-01-27	2026-01-27
Mani Mohindru	interim CEO	Appointed	2026-01-27	2026-01-27
Roger Sidhu	Chief Medical Officer	Appointed	—	2025-06-17
Roger Sidhu	Chief Medical Officer	Appointed	2025-06-17	2025-06-17
Fairooz Kabbinavar, MD, FACP	chief medical officer (CMO)	Appointed	—	2023-02-02
Fairooz Kabbinavar	Chief Medical Officer	Appointed	2023-01-30	2023-02-02

Leadership

Mani Mohindru CEO
Mani Mohindru, Ph.D. CEO
Mark Erlander CEO
Mark Erlander, Ph.D. CEO
Thomas H. Adams CEO
Rodney Markin, M.D. Chairman
James Levine CFO
Josh Muntner CFO
Joshua Muntner CFO
Ajay Aggarwal, MD, MBA COO
Vicki Kelemen COO
Brigitte Lindsay Chief Accounting Officer

Key facts CIK 1213037 CUSIP 14147L108 13F (30d) 15 filings 15 filers Visit website Investor relations